Assign an output to each recording. The following is our proposed workshop, not a claim that any episode supplies a complete procurement method.
| Workstream | Recording inputs | Required buyer output | Suggested decision boundary |
|---|---|---|---|
| Clinical and route review | Endocrine Society; JAMA; Frier Levitt; current FDA material | Exact product and arrangement, clinical responsibilities, unresolved legal questions | Do not begin price-weighted ranking while material eligibility questions remain unresolved |
| Supplier quality and provenance | NABP API/testing and counterfeit sessions | Facility-specific evidence register and exception process | Do not substitute a presentation, certificate logo or registration claim for the underlying evidence |
| Multi-state readiness | NABP telemedicine session | State-by-state responsibility and evidence matrix | Do not launch a state solely on a national-coverage claim |
| Branded access | IPC; ASHP | Patient journey, eligibility checks, payment and support ownership | Do not assume manufacturer-linked access is clinic wholesale purchasing |
| Economics | AH104 | Matched quotation workbook, separated by payer | Do not count patient savings as clinic margin |
| Continuity and implementation | PharmaSource | Pilot plan, exception tests, reporting and exit responsibilities | Do not equate a successful initial order with demonstrated ongoing capacity |
For a LillyDirect versus pharmacy-partner or NovoCare access comparison, reopen the manufacturer’s operational material rather than copying a podcast’s historical offer. Lilly describes a patient-access experience involving third-party dispensing pharmacies; NovoCare maintains a provider-facing home-delivery page. Neither page should be treated as a negotiated clinic-stock quotation. LillyDirect FAQ; NovoCare provider delivery information.
For the cost workbook, we recommend separate lines for medicine, dispensing, delivery, platform charges, failed fulfilment, wastage and internal handling. Define a successfully fulfilled patient-month explicitly—for example, the agreed supply arriving within the agreed window—and keep that operational measure separate from clinical benefit. This is a proposed comparison framework, not an industry benchmark established by these recordings.
What should the team request after listening?
- Exact contracting and dispensing entities, facility locations and intended products.
- Evidence supporting the proposed route, reviewed by the appropriate clinical and legal owners.
- Destination-state permissions and operational acceptance of the proposed prescriptions.
- A matched quotation showing introductory and ongoing terms, included services and who pays.
- Order-status reporting, escalation ownership and handling of unsuccessful orders.
- Quality, shipping, recall and complaint documentation appropriate to the arrangement.
- A controlled implementation plan and a documented patient-transition process.
- Counsel review of minimum commitments, change-in-law provisions, termination and transition assistance.
Explore the table row by row
A working view of the research
Clinical and route review
- Recording inputs
- Endocrine Society; JAMA; Frier Levitt; current FDA material
- Required buyer output
- Exact product and arrangement, clinical responsibilities, unresolved legal questions
- Suggested decision boundary
- Do not begin price-weighted ranking while material eligibility questions remain unresolved
Sources cited on this page
- lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/faq
- novocare.com · Source 2 ↗https://www.novocare.com/hcp/delivery.html